Towards new therapeutic strategies in chondrosarcoma Schrage, Y.M.

Schrage, Y.M.

Citation

Schrage, Y. M. (2009, November 5). Towards new therapeutic strategies in chondrosarcoma. Retrieved from https://hdl.handle.net/1887/14327

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/14327

Note: To cite this publication please use the final published version (if applicable).

a role for celecoxib treatment?

Yvonne M. Schrage, Isidro Machado, Danielle Meijer, Inge Briaire-de Bruijn, Brendy E. van den Akker, Antonie H.M. Taminiau, Thomas Kalinski, Antonio Llombart-Bosch, Judith V.M.G. Bovée.

Submitted



Abstract

&KRQGURVDUFRPDVDUHUHVLVWDQWWRFRQYHQWLRQDOFKHPRDQGUDGLRWKHUDS\

$ VXEVHW RI FKRQGURVDUFRPDV DULVHV VHFRQGDULO\ LQ WKH EHQLJQ WXPRXU

V\QGURPHV (QFKRQGURPDWRVLV (& DQG 0XOWLSOH 2VWHRFKRQGURPDV 02 DQG SUHYHQWLRQ RI WXPRXU GHYHORSPHQW ZRXOG JUHDWO\ LPSURYH SURJQRVLV

:H WKHUHIRUH LQYHVWLJDWHG WKH HIIHFW RI VHOHFWLYH &2; LQKLELWLRQ RQ

chondrosarcoma growth.

&2; H[SUHVVLRQ ZDV VWXGLHG LQ FHQWUDO DQG SHULSKHUDO FDUWLODJLQRXV

WXPRXUV7KHHIIHFWRI&2;LQKLELWLRQZDVDVVHVVHGLQIRXUFKRQGURVDUFRPD

FHOOOLQHVXVLQJFHOHFR[LEDQG16WUHDWPHQW&2;DFWLYLW\SURVWDJODQGLQ

(₂3*(₂(/,6$DQGFHOOYLDELOLW\ZHUHPHDVXUHG7KHSURSK\ODFWLFHIIHFW

RIFHOHFR[LERQFKRQGURVDUFRPDJURZWKin vivoZDVVWXGLHGGXULQJZHHNV

XVLQJD[HQRJUDIWPRGHORIFHOOOLQH&+LQLPPXQRLQFRPSHWHQWQXGH

mice.

+LJK &2; SURWHLQ H[SUHVVLRQ ZDV PDLQO\ IRXQG LQ VROLWDU\ SHULSKHUDO

chondrosarcoma and in enchondromatosis-related central chondrosarcoma, ZKLFK ZDV FRQÀUPHG E\ T3&5 $IWHU  KRXUV RI FHOHFR[LE WUHDWPHQW D

VLJQLÀFDQWGHFUHDVHLQFHOOYLDELOLW\ZDVREVHUYHGLQWKUHHFKRQGURVDUFRPD

cell lines. In vivoFHOHFR[LELQLWLDOO\VORZHGWXPRXUJURZWKLQFKRQGURVDUFRPD

[HQRJUDIWVKRZHYHUDIWHUSURORQJHGWUHDWPHQWUHODSVHGWXPRXUJURZWKZDV

REVHUYHG7XPRXUYROXPHZDVQHJDWLYHO\DVVRFLDWHGZLWKFHOHFR[LEVHUXP

OHYHOVDQGVHHPHGVPDOOHULQWKHKLJKGRVHSURSK\ODFWLFWUHDWPHQWJURXS

:HFRQÀUPHGH[SUHVVLRQRI&2;LQRIFKRQGURVDUFRPDVDQG&2;

LQKLELWLRQE\FHOHFR[LEGLPLQLVKHGFHOOYLDELOLW\in vitro+RZHYHUWKHin vivoGDWDVXJJHVWQRUROHIRUFHOHFR[LELQWKHWUHDWPHQWRIDGXOWKLJKJUDGH

FKRQGURVDUFRPD7KHUROHRIKLJKGRVHSURSK\ODFWLFFHOHFR[LELQSUHYHQWLQJ

GHYHORSPHQW RI EHQLJQ DQG PDOLJQDQW FDUWLODJH WXPRXUV LQ (& DQG 02

patients deserves further investigation.



Introduction

&KRQGURVDUFRPDRIERQHLVDPDOLJQDQWFDUWLODJHIRUPLQJWXPRXUZKLFK

LVKLJKO\LQVHQVLWLYHWRFODVVLFDOFKHPRWKHUDSHXWLFVDQGUDGLDWLRQWKHUDS\

&KRQGURVDUFRPDV DUH KLVWRORJLFDOO\ GLYLGHG LQWR WKUHH JUDGHV ZKLFK LV

FXUUHQWO\WKHRQO\REMHFWLYHSUHGLFWRURIPHWDVWDVLV*UDGH,WXPRXUVUDUHO\

PHWDVWDVL]HZLWKD\HDUVXUYLYDOUDWHRIZKLOH\HDUVXUYLYDOIRU

JUDGH ,,, WXPRXUV GHFUHDVHV WR  GXH WR PHWDVWDWLF GLVHDVH^ 0DUJLQDO

RU LQWUDODHVLRQDO H[FLVLRQ RI WXPRXUV FDQ UHVXOW LQ ORFDO UHFXUUHQFH ZLWK

increased histological grade²&XUUHQWO\VXUJLFDOUHPRYDORIWKHWXPRXULV

WKHRQO\RSWLRQIRUFXUDWLYHWUHDWPHQW7KHUHLVQRWUHDWPHQWZLWKFXUDWLYH

LQWHQWIRUSDWLHQWVZLWKPHWDVWDWLFGLVHDVHRULQRSHUDEOHWXPRXUV

7KHPDMRULW\RIFRQYHQWLRQDOFKRQGURVDUFRPDVDULVHLQWKHPHGXOODU

FDYLW\ RI ERQH DQG DUH GHVLJQDWHG DV SULPDU\ FHQWUDO FKRQGURVDUFRPDV³. )RU OHVV WKDQ  RI FHQWUDO FKRQGURVDUFRPDV WKHUH LV FOLQLFDO HYLGHQFH

RI D SUHH[LVWLQJ EHQLJQ HQFKRQGURPD^ (QFKRQGURPDV RFFXU PRVWO\

DVVROLWDU\OHDVLRQVDOWKRXJKWKH\PD\RFFXUDVPXOWLSOHOHDVLRQVLQWKH

FRQWH[WRIHQFKRQGURPDWRVLV2OOLHUGLVHDVHZKLFKLVDUDUHQRQKHUHGLWDU\

V\QGURPH⁵7KHULVNRIPDOLJQDQWSURJUHVVLRQLVLQFUHDVHGXSWRLQ

enchondromatosis patients^DVFRPSDUHGWRVROLWDU\HQFKRQGURPD

$W WKH VXUIDFH RI ERQH SHULSKHUDO FKRQGURVDUFRPDV DULVH VHFRQGDU\ WR

D SUHH[LVWLQJ RVWHRFKRQGURPD 0XOWLSOH RVWHRFKRQGURPDV 02 LV DQ

DXWRVRPDO GRPLQDQW KHUHGLWDU\ GLVRUGHU ZKLFK RFFXUV LQ FKLOGUHQ DQG

\RXQJDGROHVFHQWV0DOLJQDQWSURJUHVVLRQRIKHUHGLWDU\RVWHRFKRQGURPDLV

VOLJKWO\PRUHIUHTXHQWWKDQLQVROLWDU\OHDVLRQVYV3UHYHQWLQJ

new tumour formation and malignant progression in enchondromatosis and PXOWLSOHRVWHRFKRQGURPDSDWLHQWVZRXOGJUHDWO\EHQHÀWWKHLUSURJQRVLV

,QFRORUHFWDOFDQFHUDSURWHFWLYHHIIHFWRISURVWDJODQGLQV\QWKHVLVLQKLELWRUV

DOVRNQRZQDVQRQVWHURLGDODQWLLQÁDPPDWRU\GUXJV16$,'VKDVEHHQ

VXJJHVWHG DJDLQVW GHYHORSPHQW DQG JURZWK RI WKH WXPRXUV &HOHFR[LE

DQGURIHFR[LEERWKVHOHFWLYH&2;LQKLELWRUVZHUHVKRZQWRUHGXFHWKH

QXPEHUDQGVL]HRIFRORUHFWDOSRO\SVLQWKHDGMXYDQWWUHDWPHQWRI)DPLOLDO

$GHQRPDWRXV3RO\SRVLV)$3SDWLHQWV^. Also aspirin was found to have a chemopreventive effect on adenoma recurrence in patients in which a non- )$3UHODWHGDGHQRPDKDGEHHQUHPRYHG⁹16$,'VEORFNDWWDFKPHQWVLWHV

IRUDUDFKLGRQLFDFLGRQWKH&2;HQ]\PHWKHUHE\LQKLELWLQJSURVWDJODQGLQ

production^:KHUHDV&2;LVFRQVWLWXWLYHO\H[SUHVVHGXQGHUSK\VLRORJLF

FRQGLWLRQV&2;LVLQGXFHGE\F\WRNLQHVDQGIUHHUDGLFDOVPDNLQJLWD

VXLWDEOHWDUJHWIRUDQWLFDQFHUWKHUDS\

(QGR HW DO UHSRUWHG KLJK &2; H[SUHVVLRQ LQ D VXEVWDQWLDO DPRXQW RI

FKRQGURVDUFRPDVE\LPPXQRKLVWRFKHPLVWU\ZKLFKZDVDVVRFLDWHG

with high histological grade and poor prognosis^+RZHYHU6XWWRQIRXQG

QR FRUUHODWLRQ RI &2; SURWHLQ H[SUHVVLRQ DQG KLVWRORJLFDO JUDGH LQ 

FKRQGURVDUFRPDV  JUDGH , WXPRXUV  JUDGH ,, DQG  JUDGH ,,,

ZKHUHDVHQFKRQGURPDVZHUHQHJDWLYH^.



:H LQYHVWLJDWHG ZKHWKHU &2; LQKLELWLRQ

FRXOGSOD\DUROHLQHLWKHUWKHWUHDWPHQWRIKLJK

grade chondrosarcomas or the prevention of malignant progression of tumours associated ZLWK (QFKRQGURPDWRVLV RU 0XOWLSOH

Osteochondromas. Therefore we determined

&2; P51$ DQG SURWHLQ H[SUHVVLRQ LQ

patient material. We investigated the effects RI &2; LQKLELWLRQ RQ &2; SURWHLQ

H[SUHVVLRQ 3*(₂ OHYHOV DQG FHOO YLDELOLW\

LQ  KLJK JUDGH FKRQGURVDUFRPD FHOO OLQHV

in vitro. In addition, a chondrosarcoma [HQRJUDIW PRGHO RI LPPXQRLQFRPSHWHQW

QXGHPLFHZDVXVHGWRVWXG\WKHHIIHFWVRI

&2;LQKLELWLRQin vivo.

Material and methods

COX-2 expression in patient material of cartilaginous tumours

Conventional central and peripheral cartilaginous tumours were selected EDVHG RQ DFFHSWHG FOLQLFRSDWKRORJLFDO

and radiological criteria³ -X[WDFRUWLFDO

PHVHQFK\PDOGHGLIIHUHQWLDWHGDQGFOHDU

FHOO FKRQGURVDUFRPDV ZHUH H[FOXGHG ,Q

WRWDO IRUPDOLQÀ[HG SDUDIÀQHPEHGGHG

VSHFLPHQVIURPSDWLHQWV7DEOHDQG

IUHVKIUR]HQ PDWHULDO RI  SDWLHQWV ZDV

VWXGLHG+LVWRORJLFDOJUDGLQJZDVSHUIRUPHG

DFFRUGLQJ WR (YDQV^. All specimens were handled according to the ethical guidelines GHVFULEHG LQ ´&RGH IRU 3URSHU 6HFRQGDU\

8VH RI +XPDQ 7LVVXH LQ 7KH 1HWKHUODQGVµ

RIWKH'XWFK)HGHUDWLRQRI0HGLFDO6FLHQWLÀF

Societies.

&2; LPPXQRKLVWRFKHPLVWU\ 7DEOH

 RI WXPRXU WLVVXH ZDV LQGHSHQGHQWO\

VHPLTXDQWLWDWLYHO\ VFRUHG IRU F\WRSODVPLF

VWDLQLQJDVGHVFULEHGSUHYLRXVO\^, without knowledge of the clinicopathological data.

6FRUHVZHUHJLYHQIRULQWHQVLW\ ZHDN

 PRGHUDWH   VWURQJ DQG SHUFHQWDJH RI

SRVLWLYHFHOOV   

DQG 7RDYRLGWXPRXUV

CentralPeripheral 6ROLWDU\(&TOTAL6ROLWDU\02TOTALOVERALL pospospospospospospos Benign3302025 Malignant9233 Grade I CS02073 Grade II CS5025 Grade III CS - -00 - - - - - -0 ALL (Benign +Malignant)27503722 Table 6.1 COX-2 protein expression in cartilaginous tumours



ZLWKVLQJOHSRVLWLYHFHOOVEHLQJ

regarded as positive a cut- RII OHYHO RI WRWDO VXP • ZDV

applied.

51$ ZDV LVRODWHG IURP IUHVK

IUR]HQ WXPRXU WLVVXH RI 

FHQWUDOWXPRXUVDVGHVFULEHG

SUHYLRXVO\^. Growth plate VDPSOHV Q  ZHUH XVHG DV

normal counterpart controls.

0HVVHQJHU 51$ H[SUHVVLRQ

of COX-2 was studied using TXDQWLWDWLYH 573&5 IRUZDUG

primer GAATCATTCACCA-

GGCAAATTG, reverse

primer TCTGTACTGCG- GGTGGAACA DV SUHYLRXVO\

GHVFULEHG^. For normalisation

*(1250ZDVXVHG^.

Inhibition of COX-2 in chondrosarcoma in vitro Chondrosarcoma cell lines derived from chondrosarcoma JUDGH ,, 6: $PHULFDQ

7\SH &XOWXUH &ROOHFWLRQ

$7&& 0DQDVVDV 9$

JUDGH ,,, &+^ and 2806^ DQG D UHFXUUHQW

chondrosarcoma grade II in HQFKRQGURPDWRVLV &^ ZHUH FXOWXUHG LQ 530, 

VXSSOHPHQWHG ZLWK 

heat-inactivated foetal calf VHUXP *LEFR ,QYLWURJHQ

Life-Technologies, Scotland, 8. &HOO OLQH +7 $7&&

H[SUHVVLQJKLJK&2;OHYHOV

was used as a control. Cells were grown at 37ºC in a KXPLGLÀHG LQFXEDWRU ZLWK

 DLU DQG  &22. The FDUWLODJLQRXV SKHQRW\SH RI

the chondrosarcoma cell lines

AntigenCloneApplicManufac.OriginAgainstPositive controlPre- incubationSecondaryAntibody conc.AR COX-23*

,+& KXPDQ

1XFOLODE5DEELW+XPDQColorectal carcinoma

·EORFNLQJ solution*

$QWLUDEELW +53

Citrate COX-23*

,+& PRXVH

1XFOLODE5DEELW+XPDQColorectal carcinoma

·EORFNLQJ solution*

$QWLUDEELW envision*

Citrate .L0,%

,+& PRXVH

Dako0RXVH+XPDQ$Q\WXPRXUNoneAnti mouse ,J*+53Citrate Cleaved caspase-3 $VS

,+& PRXVH

Cell signalling5DEELW+XPDQBurkitt O\PSKRPDNone

$QWLUDEELW envision

Citrate

&' 3HFDP

,+& PRXVH

Santa Cruz5DEELW0RXVH$Q\·1*6

$QWLUDEELW envision

None COX-2IB

&D\PDQ chemicals

0RXVH+XPDQColorectal carcinoma

·QRQ IDWGU\PLONLQ 3%67ZHHQ

Anti mouse +53

QJ ml

7XEXOLQIB0RXVH+XPDQ$Q\

·QRQ IDWGU\PLONLQ 3%67ZHHQ Anti mouse +53 Table 6.2 Antibodies and protocols used for immunohistochemistry and immunoblotting. IRUKXPDQWLVVXHDQWLUDEELW+53ZDV XVHG,+&,PPXQRKLVWRFKHPLVWU\,%:HVWHUQEORW1*6QRUPDOJRDWVHUXP EORFNLQJVROXWLRQ07ULV00J&O7ZHHQ %6$DQGQRUPDOJRDWVHUXP$5DQWLJHQUHWULHYDO



ZDVFRQÀUPHGE\573&5VKRZLQJP51$H[SUHVVLRQRIcollagens I, 2B, 3, and 10; Aggrecan; and SOX9²⁰3URWHLQH[WUDFWLRQDQGLPPXQREORWWLQJZHUH

SHUIRUPHG DV GHVFULEHG SUHYLRXVO\^ $ :67 FRORULPHWULF DVVD\ 5RFKH

'LDJQRVWLFV*PE+3HQ]EHUJ*HUPDQ\ZDVXVHGDVGHVFULEHGSUHYLRXVO\^

WR PHDVXUH PHWDEROLF DFWLYLW\ UHSUHVHQWLQJ WKH DPRXQW RI YLDEOH FHOOV LQ

UHVSRQVH WR FHOHFR[LE 3À]HU 1< 86$ DQG 16 &D\PDQ FKHPLFDOV

$QQ$UERU0,86$ ³FKRQGURVDUFRPDFHOOV&+2806DQG

& DQG  ³ +7 DQG 6: FHOOV ZHUH VHHGHG &HOHFR[LE DQG

16ZHUHGLOXWHGLQ'062$IWHUKRXUVLQFUHDVLQJFRQFHQWUDWLRQV

RIWKHGUXJVZHUHDGGHGDQGǍ0RU'062&ZDVQRW

LQFOXGHGLQWKH16DVVD\

)RUPHDVXULQJ3*(₂OHYHOVFHOOVRI2806&+&DQG+7

ZHUHVHHGHGLQDZHOOVSODWHDWDGHQVLW\RI ^DQG6:DWD

GHQVLW\RI ^7ZHQW\IRXUKRXUVDIWHUVHHGLQJFHOOVZHUHWUHDWHGZLWK

FHOHFR[LELQLQFUHDVLQJGRVDJHVDQGǍ0RUZLWK'062$IWHU

KRXUV3*(₂FRQFHQWUDWLRQLQWKHPHGLXPZDVGHWHUPLQHGE\D3*(₂- VSHFLÀFHQ]\PHOLQNHGLPPXQRDVVD\&D\PDQFKHPLFDOV$QQ$UERU0,

86$DFFRUGLQJWRWKHPDQXIDFWXUHU·VSURWRFROP51$ZDVH[WUDFWHGDQG

&<3$P51$OHYHOVZHUHGHWHUPLQHGWRDVVHVVDURPDWDVHDFWLYLW\²⁰. Five SHUFHQWVHUXPVXSSOHPHQWDWLRQZDVXVHGIRUDOOH[SHULPHQWV

In vivo chondrosarcoma model

6L[W\ 6ZLVV PDOH QXGH PLFH &UO18,FR)R[QQX ,))$&5('2 /\RQ

)UDQFH ZHUH UDQGRPO\ DVVLJQHG WR RQH RI ÀYH JURXSV )LJXUH  /RZ

GRVHV FRQWDLQHG SSP FHOHFR[LE KLJK GRVHV SSP 7KH VHOHFWLYH

&2; LQKLELWRU FHOHFR[LE &6 ZDV LQFRUSRUDWHG LQWR D PRGLÀHG

QXGH PRXVH GLHW $OWURPLQ *HVHOOVFKDIW IXU 7LHUHUQDKUXQJ PE+ /DJH

*HUPDQ\DQGLUUDGLDWHGWRDFFRPSOLVKVWHULOLW\0LFHZHUHDEOHWRIHHGDQG

GULQN DG OLELWXP $PRXQW RI IRRG FRQVXPHG ZDV PRQLWRUHG LQGLYLGXDOO\

3URSK\OD[LVZDVVWDUWHGGD\VSULRUWRLQRFXODWLRQDVVWHDG\VWDWHOHYHOV

RIFHOHFR[LEDUHUHDFKHGLQÀYHGD\VLQKXPDQV3À]HU$WZHHNDOOPLFH

ZHUHLQMHFWHGZLWK ^&+FHOOVVXEFXWDQHRXVO\RQWKHEDFN6LQFH

FKRQGURVDUFRPDV KDYH D UHODWLYHO\ VORZ JURZWK UDWH ZH ZDLWHG  GD\V

IRUWKHWXPRXUVWRUHDFKDVL]HODUJHHQRXJKIRUH[WHUQDODQDO\VLVEHIRUH

WUHDWPHQW ZLWK FHOHFR[LE ZDV VWDUWHG 7UHDWPHQW ZDV SURORQJHG IRU 

GD\V DIWHU ZKLFK WKH PLFH ZHUH VDFULÀFHG 7KH PLFH ZHUH ZHLJKWHG RQFH

a week. Calipers were used to measure the tumour volume in vivo using WKHIROORZLQJIRUPXODOHQJWK ZKLWK²%ORRGVDPSOHVREWDLQHGE\DRUWDO

SXQFWLRQDWWLPHRIVDFULÀFHZHUHDOORZHGWRFRDJXODWHDQGZHUHFHQWULIXJHG

IRUPLQXWHVDWUSPVXSHUQDWDQWVZHUHFROOHFWHGDQGVWRUHGDW

ƒ&XQWLO+3/&DQDO\VLV+3/&ZDVSHUIRUPHGE\&DVH%HO%RUJHUKRXW

%HOJLXPDVGHVFULEHGSUHYLRXVO\²².

7KHH[FLVHGWXPRXUVZHUHÀ[HGLQIRUPDOLQIRUKRXUVDQGHPEHGGHG

LQSDUDIÀQ7RVWXG\SRVVLEOHWR[LFLW\RIFHOHFR[LEWLVVXHRIWKHKHDUWOXQJV



OLYHUDQGNLGQH\ZHUHWDNHQDWDXWRSV\IRUKLVWRORJLFDODQDO\VLV;HQRJUDIWHG

WXPRXUVZHUHDQDO\VHGE\+ (7ROXLGLQHEOXHDQGLPPXKLVWRFKHPLVWU\

IRU&2;.LFOHDYHGFDVSDVHDQG&'7DEOH&2;VWDLQLQJ

ZDVVFRUHGDVQHJDWLYHYHU\ZHDNRUSRVLWLYH.LDQGFOHDYHGFDVSDVH

VWDLQLQJ ZHUH GLJLWDOO\ VFRUHG XVLQJ FRQIRFDO PLFURVFRS\ 1XDQFH 

&DPEULGJH UHVHDUFK DQG ,QVWUXPHQWDWLRQ ,QF :REXUQ 0$ 86$ $

minimum of 2000 cells were counted and the percentage of positive cells ZDV DXWRPDWLFDOO\ FDOFXODWHG ,PDJH- 9 :D\QH 5DVEDQG 1DWLRQDO

,QVWLWXWHV RI +HDOWK 86$ WR DVVHVV PLFURYHVVHO GHQVLW\ &'SRVLWLYH

YHVVHOVZHUHFRXQWHGLQKLJKSRZHUÀHOGVSHUWXPRXU$QLQGHSHQGHQW

H[SHULPHQWZDVSHUIRUPHGXVLQJJUDGH,,FKRQGURVDUFRPD[HQRJUDIWPRGHO

ZLWKKLJKFHOHFR[LESURSK\OD[LVQ DQGWUHDWPHQWQ JURXS

Statistics

&RPSDULVRQ EHWZHHQ JURXSV ZDV SHUIRUPHG XVLQJ 3HDUVRQ &KL6TXDUH

LPPXQRKLVWRFKHPLVWU\ DQG 6WXGHQWV·V WWHVW 573&5 3 YDOXHV 

ZHUHFRQVLGHUHGVLJQLÀFDQW

Results

Higher COX-2 expression in chondrosarcoma and in enchondromatosis.

,Q WRWDO LQ  RI WKH FKRQGURVDUFRPDV WXPRXU FHOOV GHPRQVWUDWHG

F\WRSODVPLF &2; SURWHLQ H[SUHVVLRQ )LJXUH $ 0DOLJQDQW WXPRXUV

ZHUH PRUH RIWHQ SRVLWLYH IRU &2; WKDQ EHQLJQ WXPRXUV  YV 

S IRUFHQWUDODQGYVS IRUSHULSKHUDO3HDUVRQ&KL

6TXDUH ,Q WKH JURXS RI FHQWUDO FKRQGURVDUFRPDV SRVLWLYLW\ ZDV PDLQO\

VHHQ LQ HQFKRQGURPDWRVLVUHODWHG FKRQGURVDUFRPDV  ZKHUHDV

SHULSKHUDO VROLWDU\ WXPRXUV ZHUH PRUH RIWHQ SRVLWLYH  WKDQ 02

UHODWHGFKRQGURVDUFRPDV5HVXOWVDUHVXPPDULVHGLQWDEOH

$OVRDWP51$OHYHOHQFKRQGURPDWRVLVUHODWHGWXPRXUVWHQGWRVKRZKLJKHU

&2; H[SUHVVLRQ DV FRPSDUHG WR VROLWDU\ WXPRXUV S  6WXGHQW·V

WWHVW )LJXUH % +RZHYHU QR GLIIHUHQFH LQ &2; P51$ H[SUHVVLRQ

EHWZHHQEHQLJQQ DQGPDOLJQDQWWXPRXUVQ ZDVIRXQG6WXGHQW·V

WWHVWS QRWVKRZQ

Figure 6.16L[W\LPPXQRLQFRP- SHWHQWQXGHPLFHZHUHUDQGRPO\

DVVLJQHGWRHLWKHUSURSK\ODFWLFORZ

GRVHFHOHFR[LE3/;BORZSURSK\ODF- WLFKLJKGRVHFHOHFR[LE3/;BKLJK

WUHDWPHQWORZGRVHFHOHFR[LE750B ORZWUHDWPHQWKLJKGRVHFHOHFR[LE

3/;BKLJKRUFRQWUROJURXS&RQ- WURO



COX-2 inhibitors decrease proliferation of chondrosarcomas in vitro

$OOIRXUFKRQGURVDUFRPDFHOOOLQHVGHPRQVWUDWHG&2;SURWHLQH[SUHVVLRQ

LQYDULDEOHOHYHOV)LJXUH$$IWHUKRXUVRIǍ0FHOHFR[LEWUHDWPHQW

DGHFUHDVHLQFHOOYLDELOLW\ZDVREVHUYHGFRPSDUDEOHWR+7LQWKHWKUHH

FHOOOLQHVWKDWZHUHGHULYHGIURPVROLWDU\WXPRXUV)LJXUH%)RU2806

DGHFUHDVHLQFHOOYLDELOLW\ZDVREVHUYHGDOUHDG\DWǍ0FHOHFR[LE&

GLGQRWUHVSRQGWRFHOHFR[LE)LJXUH%QRWHYHQZKHQWUHDWPHQWZDV

SURORQJHGIRUKRXUVGDWDQRWVKRZQ(IIHFWVRI16ZHUHPRUHVXEWOH

)LJXUH&

Response to celecoxib is independent of COX-2 activity

%\3*(₂(/,6$ZHVKRZHGWKDWLQ&+2806DQG&WKH&2;

HQ]\PHV DUH DFWLYH DQG WKDW D GRVH RI  Ǎ0 FHOHFR[LE ZDV HQRXJK WR

VLJQLÀFDQWO\GHFUHDVH3*(₂OHYHOV)LJXUH'5HPDUNDEO\ZHZHUHQRW

DEOHWRGHWHFW&2;DFWLYLW\LQ+7DQG6:ZKLFKERWKUHVSRQGHG

ZHOOWRFHOHFR[LEWUHDWPHQW5HODWLYH&<3$P51$OHYHOVZHUHGHFUHDVHG

WZRIROG XSRQ FHOHFR[LE WUHDWPHQW LQ 6: ZKHUHDV LQ &+ DQG

&&<3$OHYHOVZHUHLQFUHDVHGWZRIROGGDWDQRWVKRZQ

Figure 6.2 $ &\WRSODVPLF &2; H[- pression in central chondrosarcoma JUDGH,%&2;P51$ZDVKLJKHUH[- pressed in central cartilaginous tumours FRPSDUHG WR JURZWK SODWH *3 VDPSOHV

and tumours related to enchondroma- WRVLV (& VKRZHG KLJKHU H[SUHVVLRQ RI

&2;WKDQVROLWDU\WXPRXUV



Celecoxib initially slows tumour growth in chondrosarcoma xenografts During the in vivo VWXG\DOOPLFHKDGFRPSDUDEOHERG\ZHLJKWVDQGDPRXQWV

RIIRRGDGPLQLVWHUHG$6L[PLFHGLHGGXULQJWKHH[SHULPHQWVERWKLQ

WKHFHOHFR[LEDQGWKHFRQWUROJURXSV6HUXPOHYHOVRIFHOHFR[LEFRUUHVSRQGHG

WRWKHGRVHRIFHOHFR[LEDGPLQLVWHUHGDOWKRXJKOHYHOVZHUHYDULDEOH)LJXUH

%7XPRXUVL]HZDVQHJDWLYHO\FRUUHODWHGWRFHOHFR[LEVHUXPOHYHOV

U )LJXUH&$WZHHNVWKHWXPRXUYROXPHVHHPHGVPDOOHULQ

WKH JURXSV UHFHLYLQJ FHOHFR[LE SURSK\OD[LV ZKLFK ZDV VLJQLÀFDQW IRU WKH

KLJK GRVH  DV FRPSDUHG WR WKH FRQWURO JURXS 6WXGHQW·V WWHVW S 

ORZGRVHDQGS KLJKGRVHUHVSHFWLYHO\)LJXUH'+LVWRORJLFDO

HYDOXDWLRQRIWKHKHDUWOXQJVOLYHUVSOHHQDQGNLGQH\VRIWKHPLFHGLGQRW

UHYHDODQ\VLJQVRIWR[LFLW\

Relapse of tumour growth in xenografts after prolonged treatment

$W ZHHN  D UHODSVH ZDV REVHUYHG PRVW FOHDUO\ LQ WKH ORZ FHOHFR[LE

SURSK\OD[LV DQG WUHDWPHQW JURXSV $W WKH HQG RI WKH H[SHULPHQW ZHHN

RQO\WKHKLJKSURSK\OD[LVJURXSVKRZHGVPDOOHUWXPRXUYROXPHVWKDQ

WKHFRQWUROJURXS)LJXUH(+RZHYHUGXHWRODUJHYDULDWLRQLQWXPRXU

volume within the groups, statistical calculations are not meaningful. The JURZWKFXUYHVRIWKHWXPRXUVVKRZHGWKDWDWZHHNWKHWXPRXUVVWDUWHG

WRJURZHYHQIDVWHUWKDQWKHFRQWUROJURXS)LJXUH)7KLVZDVH[DFWO\

WKH WLPH SRLQW DW ZKLFK WKH JURZWK FXUYHV RI WKH PLFH ÁDWWHQHG )LJXUH

Figure 6.3$&2;SURWHLQH[SUHVVLRQLQFHOOOLQHV%GHFUHDVHGYLDELOLW\6:2806

DQG&+XSRQǍ0FHOHFR[LEWUHDWPHQW&16KDVDPRGHUDWHHIIHFWG&2;DF- WLYLW\LVDEVHQWLQ6:DQGGHFUHDVHGXSRQǍ0FHOHFR[LEWUHDWPHQWLQ2806&+

DQG&



$ VXJJHVWLQJ WKH HQG RI SXEHUW\ 7KH LQGHSHQGHQW H[SHULPHQWV LQ

ZKLFKKLJKFHOHFR[LEGRVHVZHUHXVHGVKRZHGVLPLODUUHVXOWVIRUWKHJUDGH

,,FKRQGURVDUFRPD[HQRJUDIWPRGHOGDWDQRWVKRZQ Evaluation of tumour tissue

7XPRXUVZHUHKLJKO\FHOOXODUZLWKOLPLWHGF\WRQXFOHDUDW\SLDDQGDOLPLWHG

DPRXQW RI H[WUDFHOOXODU PDWUL[ )LJXUH $ 7ROXLGLQHEOXH VWDLQLQJ

FRQÀUPHG WKH GHSRVLWLRQ RI SURWHRJO\FDQV )LJXUH % :KHUHDV LQ DOO

FHOHFR[LEWUHDWHGJURXSV&2;VWDLQLQJZDVDEVHQWRUYHU\ZHDN)LJXUH

&VWURQJ&2;H[SUHVVLRQZDVREVHUYHGLQRIWKHFRQWUROWXPRXUV

Figure 6.4$0LFHERG\ZHLJKWLQFUHDVHVWLOOZHHN%&HOHFR[LEEORRGOHYHOVFRUUHVSRQG

WRFHOHFR[LEGRVH&WXPRXUYROXPHLVQHJDWLYHO\FRUUHODWHGZLWKFHOHFR[LEVHUXPOHYHOV

U '/RZHUWXPRXUYROXPHLQSURSK\OD[LVJURXSDWZHHN(WXPRXUVH[SRVHGWR

ORZGRVHFHOHFR[LEDUHODUJHUWKDQFRQWUROVDWZHHNDOWKRXJKYDULDWLRQZLWKLQWKHJURXSV

LVFRQVLGHUDEOH)2YHUDOOJURZWKFXUYHRIWKHWXPRXUVVKRZLQJUHODSVHDWZHHNIRUWKRVH

H[SRVHGWRORZGRVHFHOHFR[LE VLJQLÀFDQWO\GLIIHUHQWIURPFRQWUROV



)LJXUH'3UROLIHUDWLRQZDVVHHQLQDOOJURXSV)LJXUH(ZLWKKLJKHU

.LH[SUHVVLRQLQWKHWUHDWHGWXPRXUVDWZHHN6WXGHQW·VWWHVWORZGRVH

S DQGKLJKGRVHS $VWHULVNVÀJXUH)&OHDYHGFDVSDVH

H[SUHVVLRQ ZDV ORZ PHDQ  UDQJH  DV ZDV PLFURYHVVHO

GHQVLW\PHDQSHUKSIUDQJHSHUKSIDQGQRGLIIHUHQFHV

EHWZHHQJURXSVZHUHIRXQG)LJXUHV*+

Discussion

Since there is nothing to offer with curative intent to patients with PHWDVWDWLFRULQRSHUDEOHFKRQGURVDUFRPDWKHUHLVDGHVSHUDWHQHHGIRUQHZ

therapeutic options. Furthermore, the prevention of development of new WXPRXUV DQG HVSHFLDOO\ RI PDOLJQDQW WUDQVIRUPDWLRQ RI EHQLJQ SUHFXUVRU

leasions in patients with enchondromatosis and multiple osteochondromas ZRXOGJUHDWO\LPSURYHWKHSURJQRVLVRIWKHVHFKLOGUHQDQG\RXQJDGXOWV,Q

WKLVVWXG\ZHLQYHVWLJDWHGWKHSRWHQWLDORIVHOHFWLYH&2;LQKLELWLRQIRUWKH

treatment of chondrosarcoma.

:H GHPRQVWUDWHG H[SUHVVLRQ RI &2; LQ D VXEVHW RI HQFKRQGURPDV

 RVWHRFKRQGURPDV  DQG FHQWUDO  DQG SHULSKHUDO  FKRQGURVDUFRPDV FRQÀUPLQJ SXEOLVKHG UHVXOWV^ ,QWHUHVWLQJO\ &2;

 SURWHLQ DQG P51$ H[SUHVVLRQ ZDV PDLQO\ IRXQG LQ HQFKRQGURPDWRVLV

UHODWHGWXPRXUVZKHUHDVFRUUHODWLRQZLWKKLVWRORJLFDOJUDGHFRXOGQRWEH

FRQÀUPHG

&KRQGURVDUFRPDFHOOYLDELOLW\GHFUHDVHGDIWHUDGPLQLVWUDWLRQRIKLJKVXSHU

SK\VLRORJLFOHYHOVRIFHOHFR[LEDQG16ZKLOHDSK\VLRORJLFGRVDJHRI

FHOHFR[LEZDVDEOHWRDEROLVKPRVW&2;DFWLYLW\LQWKUHHFHOOOLQHV'HVSLWH

WKHODFNRI&2;DFWLYLW\LQ6:DGHFUHDVHLQFHOOYLDELOLW\ZDVIRXQG

LQUHVSRQVHWRFHOHFR[LEZKLFKVXJJHVWVD&2;LQGHSHQGHQWPHFKDQLVP

ZKLFKZDVSUHYLRXVO\VXJJHVWHGIRUFRORUHFWDOFDQFHUUHYLHZHGE\*URVFKHW

al.²³,QEUHDVWFDQFHU&2;LQKLELWRUVZHUHIRXQGWRVXSSUHVVDURPDWDVH

DFWLYLW\LQERWKD3*(₂ dependent and independent manner^, and Cleton- -DQVHQ HW DO VKRZHG WKDW FKRQGURVDUFRPD JURZWK FRXOG EH LQKLELWHG E\

DURPDWDVHLQKLELWRUVin vitro²⁰7KHGHFUHDVHLQ&<3$DFWLYLW\LQ6:

GXULQJ FHOHFR[LE WUHDWPHQW VXJJHVWV WKDW WKLV JURZWK LQKLELWRU\ HIIHFW LV

H[HUWHGYLDWKHLQKLELWLRQRIDURPDWDVH

6LQFHWKUHHRIIRXUFKRQGURVDUFRPDFHOOOLQHVUHVSRQGHGWRFHOHFR[LEin vitro, ZHDOVRWHVWHGFHOHFR[LELQFKRQGURVDUFRPD[HQRJUDIWV&HOHFR[LEWUHDWPHQW

ZDVLQLWLDOO\HIIHFWLYHLQVORZLQJWKHJURZWKUDWHRIFKRQGURVDUFRPD0RUHRYHU

WXPRXUVL]HZDVLQYHUVHO\FRUUHODWHGZLWKFHOHFR[LEVHUXPOHYHOVPHDVXUHG

DWWKHHQGRIWKHH[SHULPHQW+RZHYHUDUHODSVHZDVREVHUYHGLQZHHN

ZKLFKZDVHVSHFLDOO\SURPLQHQWLQWKHPLFHUHFHLYLQJORZGRVHFHOHFR[LE

In addition, the treated tumours showed an increased proliferation rate.

,QWHUHVWLQJO\DWZHHNWKHJURZWKFXUYHRIWKHPLFHÁDWWHQHGVXJJHVWLQJ

WKHHQGRISXEHUW\ZKLFKVXJJHVWVKRUPRQDOLQÁXHQFHVRQWXPRXUJURZWK

+HUHWKLVHIIHFWFDQQRWEHDWWULEXWHGWRHVWURJHQVVLQFH&+LVHVWURJHQ



receptor negative^.

2QHRIWKHPHFKDQLVPVRIWXPRXULQKLELWLRQRIFHOHFR[LELVWKRXJKWWREHWKH

LQKLELWLRQRIDQJLRJHQHVLV7KHUHODSVHDWZHHNPLJKWUHÁHFWDWLPHSRLQW

ZKHUHFHOHFR[LEFDQQRORQJHULQKLELWDQJLRJHQHVLVDOORZLQJYHVVHOLQJURZWK

$W VDFULÀFH QR GLIIHUHQFHV LQ PLFURYHVVHO GHQVLW\ ZHUH IRXQG VXJJHVWLQJ

WKDW HLWKHU GLIIHUHQFHV LQ PLFURYHVVHO GHQVLW\ DUH FRPSOHWHO\ RYHUFRPH RU

D GLIIHUHQW PHFKDQLVP ZDV UHVSRQVLEOH IRU WKH LQLWLDO GHFUHDVHG WXPRXU

JURZWK8QIRUWXQDWHO\ZHZHUHQRWDEOHWRVWXG\WXPRXUFKDUDFWHULVWLFVRU

EORRGSDUDPHWHUVGXULQJWKHH[SHULPHQW

,Q DQDORJ\ WR WKH SUHYHQWLRQ RI QHZ DGHQRPD IRUPDWLRQ LQ IDPLOLDO

DGHQRPDWRXV SRO\SRVLV SUHYHQWLRQ RI GHYHORSPHQW DQG PDOLJQDQW

transformation of enchondromas and osteochondromas in patients with HQFKRQGURPDWRVLV DQG PXOWLSOH RVWHRFKRQGURPDV PLJKW EH EHQHÀFLDO

$OWKRXJKZHVKRZHG&2;H[SUHVVLRQWREHKLJKHULQHQFKRQGURPDWRVLV

UHODWHG WXPRXUV FRPSDUHG WR VROLWDU\ WXPRXUV WKH HQFKRQGURPDWRVLV

GHULYHGFHOOOLQH&GLGQRWUHVSRQGWRFHOHFR[LEWUHDWPHQWin vitro. In YLYRDJURZWKLQKLELWLQJHIIHFWZDVVKRZQLQWKHÀUVWZHHNVRIWKHVWXG\LQ

WKHSUHSXEHUWDOPLFHZKLFKZDVDEROLVKHGDWWKHPRPHQWWKHPLFHUHDFKHG

DGXOWKRRG7KLVPLJKWVXJJHVWWKDWFHOHFR[LELVPRUHHIIHFWLYHLQSUHSXEHUWDO

SDWLHQWV0RUHRYHUWKHUHZDVDWUHQGIRUKLJKGRVHSURSK\ODFWLFFHOHFR[LE

WUHDWPHQWWRKDYHVPDOOHUWXPRXUVDWWKHHQGRIWKHVWXG\+RZHYHUWKH

KLJKGRVHSURSK\OD[LVJURXSVKRZHGDKLJKHUSUROLIHUDWLRQUDWHDVFRPSDUHG

to the control. Thus, our results are not conclusive on whether the paediatric population of multiple osteochondromas and enchondromatosis patients PLJKW EHQHÀW IURP FHOHFR[LE WUHDWPHQW DQG IXUWKHU VWXGLHV VKRXOG EH

SHUIRUPHG,QDGGLWLRQLWVKRXOGEHQRWHGWKDWRXUPRGHOLVVXERSWLPDOWR

VWXG\WKHHIIHFWRIFHOHFR[LERQSUHYHQWLRQRIPDOLJQDQWWUDQVIRUPDWLRQVLQFH

ZHXVHGKLJKJUDGHFKRQGURVDUFRPD[HQRJUDIWV8QIRUWXQDWHO\WKHUHLVQR

VXLWDEOHin vivo model for enchondromatosis or multiple osteochondromas, DQG[HQRJUDIWVIURPORZJUDGHFKRQGURVDUFRPDVDUHGLIÀFXOWWRREWDLQ

'XULQJ ORQJWHUP FOLQLFDO WULDOV &2; LQKLELWRUV ZHUH VKRZQ WR KDYH

FDUGLRYDVFXODUVLGHHIIHFWV&HOHFR[LEWULDOVZHUHGLVFRQWLQXDWHGHDUOLHU²⁵ and URIHFR[LEZDVZLWKGUDZQE\WKH)'$^+RZHYHUFKLOGUHQDQGDGROHVFHQWV

DUHDWORZULVNRIFDUGLRYDVFXODUGLVHDVHZKLFKUHQGHUVWKHXVHRIFHOHFR[LE

UHODWLYHO\VDIH$FFRUGLQJO\FHOHFR[LELVSUHVFULEHGWRMXYHQLOHUKHXPDWRLG

DUWKULWLV SDWLHQWV IURP WKH DJH RI  \HDUV UHYLHZHG LQ )UDPSWRQ HW DO²⁷

1H[WWRLWVSRWHQWLDODQWLWXPRXUHIIHFWFHOHFR[LEVDQDOJHWLFHIIHFWZLOOEH

EHQHÀFLDOIRUPXOWLSOHRVWHRFKRQGURPDVDQGHQFKRQGURPDWRVLVSDWLHQWV

left page Figure 6.5$+ (VWDLQLQJRIWKH&+[HQRJUDIW%7ROXLGLQHEOXHVWDLQLQJ

FRQÀUPHGSURWHRJO\FDQFRQWHQW&$EVHQWRUYHU\ZHDN&2;VWDLQLQJLQWUHDWHGWXPRXUV

'VWURQJ&2;VWDLQLQJLQRIWKHFRQWUROV()+LJKHUSUROLIHUDWLRQUDWH.LLQWKH

FHOHFR[LEWUHDWHGWXPRXUV*&DVSDVHPHGLDWHGDSRSWRVLVLVOLPLWHG+0LFURYHVVHOV

GHWHFWHGE\&'



,QFRQFOXVLRQZHFRQÀUPHGH[SUHVVLRQRI&2;LQRIFKRQGURVDUFRPDV

DQG &2; LQKLELWLRQ GLPLQLVKHG FHOO YLDELOLW\ in vitro, although this ZDV LQGHSHQGHQW RI &2; DFWLYLW\ +RZHYHU XVLQJ D JUDGH ,, DQG ,,,

FKRQGURVDUFRPD [HQRJUDIW PRGHO ZH REVHUYHG D VZLWFK IURP WXPRXU

LQKLELWRU\ WR WXPRXU SURPRWLQJ HIIHFWV ZKHQ PLFH UHDFKHG DGXOWKRRG

VXJJHVWLQJWKDWHYHQWKRXJKWXPRXUYROXPHZDVQHJDWLYHO\DVVRFLDWHGZLWK

FHOHFR[LEVHUXPOHYHOVWKHUHLVQRUROHIRUFHOHFR[LELQWKHWUHDWPHQWRIDGXOW

KLJKJUDGH FKRQGURVDUFRPD 7KH UROH RI KLJKGRVH SURSK\ODFWLF FHOHFR[LE

LQ SUHYHQWLQJ GHYHORSPHQW RI EHQLJQ DQG PDOLJQDQW FDUWLODJH WXPRXUV LQ

SUHSXEHUWDO(&DQG02SDWLHQWVGHVHUYHVIXUWKHULQYHVWLJDWLRQ

Acknowledgements

7KHDXWKRUVOLNHWRWKDQN3-..XSSHQ'HSDUWPHQWRI6XUJHU\/80&

7KH1HWKHUODQGV3&:+RJHQGRRUQ'HSDUWPHQWRI3DWKRORJ\/80&7KH

1HWKHUODQGV0.DUSHULHQ'HSDUWPHQWRI7LVVXH5HJHQHUDWLRQ8QLYHUVLW\

RI7ZHQWH7KH1HWKHUODQGVDQG&(3$VVHOEHUJV'HSDUWPHQWRI6XUJHU\

/80& 7KH 1HWKHUODQGV IRU IUXLWIXO GLVFXVVLRQ DQG ) 3ULQV $ YDQ GHU

:DODQG3:LMHUV.RVWHUIRUH[FHOOHQWWHFKQLFDODVVLVWDQFH

*UDQWVXSSRUW1HWKHUODQGV2UJDQLVDWLRQIRU6FLHQWLÀF5HVHDUFK>

 <06 DQG  WR -90*%@ 7KLV VWXG\ ZDV SHUIRUPHG

ZLWKLQ WKH FRQWH[W RI WKH (XUR%R1H7 FRQVRUWLXP >@ D (XURSHDQ

&RPPLVVLRQJUDQWHG1HWZRUNRI([FHOOHQFHIRUVWXG\LQJWKHSDWKRORJ\DQG

JHQHWLFVRIERQHWXPRXUV

Reference List

  (YDQV+/$\DOD$*5RPVGDKO003URJQRVWLFIDFWRUVLQFKRQGURVDUFRPD

RI ERQH $ FOLQLFRSDWKRORJLF DQDO\VLV ZLWK HPSKDVLV RQ KLVWRORJLF JUDGLQJ

Cancer

  %ULHQ(:0LUUD-0/XFN-9-U%HQLJQDQGPDOLJQDQWFDUWLODJHWXPRXUV

RIERQHDQGMRLQWWKHLUDQDWRPLFDQGWKHRUHWLFDOEDVLVZLWKDQHPSKDVLVRQ

UDGLRORJ\SDWKRORJ\DQGFOLQLFDOELRORJ\,,-X[WDFRUWLFDOFDUWLODJHWXPRXUV

Skeletal Radiol

  %HUWRQL)%DFFKLQL3+RJHQGRRUQ3&:&KRQGURVDUFRPD,Q)OHWFKHU&'0

8QQL .. 0HUWHQV ) HGLWRUV :RUOG +HDOWK 2UJDQLVDWLRQ FODVVLÀFDWLRQ RI

WXPRXUV 3DWKRORJ\ DQG JHQHWLFV RI WXPRXUV RI VRIW WLVVXH DQG ERQH/\RQ

,$5&3UHVVS

  /XFDV'5%ULGJH-$&KRQGURPDVHQFKRQGURPDSHULRVWHDOFKRQGURPDDQG

HQFKRQGURPDWRVLV ,Q )OHWFKHU &'0 8QQL .. 0HUWHQV ) HGLWRUV :RUOG

+HDOWK 2UJDQL]DWLRQ FODVVLÀFDWLRQ RI WXPRXUV 3DWKRORJ\ DQG JHQHWLFV RI

WXPRXUVRIVRIWWLVVXHDQGERQH/\RQ,$5&3UHVVS

  2OOLHU0'\VFKRQGURSODVLHLyon Med

  6FKZDUW] +6 =LPPHUPDQ 1% 6LPRQ 0$ :UREOH 55 0LOODU ($ %RQÀJOLR

0 7KH PDOLJQDQW SRWHQWLDO RI HQFKRQGURPDWRVLV J Bone Joint Surg Am



  6WHLQEDFK*/\QFK303KLOOLSV5.:DOODFH0++DZN(*RUGRQ*%HWDO

7KHHIIHFWRIFHOHFR[LEDF\FORR[\JHQDVHLQKLELWRULQIDPLOLDODGHQRPDWRXV

SRO\SRVLVN Engl J Med



  9DQ6WRON56WRQHU*+D\WRQ:/&KDQ.'H<RXQJ%.UHVW\/HWDO3KDVH

,WULDORIH[LVXOLQGVXOLQGDFVXOIRQH)*1DVDFKHPRSUHYHQWLYHDJHQWLQ

SDWLHQWVZLWKIDPLOLDODGHQRPDWRXVSRO\SRVLVClin Cancer Res

  %DURQ -$ &ROH %) 6DQGOHU 56 +DLOH 5: $KQHQ ' %UHVDOLHU 5 HW DO $

randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med



 6PLWK :/ 0DUQHWW /- 'H:LWW '/ 3URVWDJODQGLQ DQG WKURPER[DQH

ELRV\QWKHVLVPharmacol Ther

 (QGR00DWVXPXUD7<DPDJXFKL7<DPDJXFKL80RULPRWR<1DNDWDQL

)HWDO&\FORR[\JHQDVHRYHUH[SUHVVLRQDVVRFLDWHGZLWKDSRRUSURJQRVLVLQ

chondrosarcomas. Hum Pathol

 6XWWRQ.0:ULJKW0)RQGUHQ*7RZOH&$0DQNLQ+-&\FORR[\JHQDVH

H[SUHVVLRQLQFKRQGURVDUFRPDOncology

 %RYpH-90*&OHWRQ-DQVHQ$0.XLSHUV'LMNVKRRUQ19DQGHQ%URHN/-&0

7DPLQLDX$+0&RUQHOLVVH&-HWDO/RVVRIKHWHUR]\JRVLW\DQG'1$SORLG\

point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chrom Cancer

 %DHOGH+-&OHWRQ-DQVHQ$0YDQ%HHUHQGRQN+1DPED0%RYpH-90*

+RJHQGRRUQ3&:+LJKTXDOLW\51$LVRODWLRQIURPWXPRXUVZLWKORZFHOOXODULW\

DQGKLJKH[WUDFHOOXODUPDWUL[FRPSRQHQWIRUF'1$PLFURDUUD\VDSSOLFDWLRQWR

chondrosarcoma. J Clin Pathol

 +DPHHWPDQ/5R]HPDQ/%/RPEDHUWV02RVWLQJ-7DPLQLDX$+0&OHWRQ

-DQVHQ$0HWDO3HULSKHUDOFKRQGURVDUFRPDSURJUHVVLRQLVDFFRPSDQLHGE\

GHFUHDVHG,QGLDQ+HGJHKRJ,++VLJQDOOLQJJ Pathol

 9DQGHVRPSHOH - 'H 3UHWHU . 3DWW\Q ) 3RSSH % 9DQ 5R\ 1 'H 3DHSH

$ HW DO $FFXUDWH QRUPDOL]DWLRQ RI UHDOWLPH TXDQWLWDWLYH 573&5 GDWD

E\ JHRPHWULF DYHUDJLQJ RI PXOWLSOH LQWHUQDO FRQWURO JHQHV Genome Biol

UHVHDUFK

 *LO%HQVR 5 /RSH]*LQHV & /RSH]*XHUUHUR -$ &DUGD & &DOODJKDQ 5&

1DYDUUR6HWDO(VWDEOLVKPHQWDQGFKDUDFWHUL]DWLRQRIDFRQWLQXRXVKXPDQ

FKRQGURVDUFRPDFHOOOLQHFKFRPSDUDWLYHKLVWRORJLFDQGJHQHWLFVWXGLHV

with its tumour of origin. Lab Invest

 .XQLVDGD70L\D]DNL00LKDUD.*DR&.DZDL$,QRXH+HWDO$QHZ

KXPDQ FKRQGURVDUFRPD FHOO OLQH 2806 WKDW PDLQWDLQV FKRQGURF\WLF

differentiation. Int J Cancer

 .DOLQVNL 7 .UXHJHU 6 3HO] $) :LHDFNHU 3 +DUWLJ 5 5RSNH 0 HW DO

(VWDEOLVKPHQWDQGFKDUDFWHUL]DWLRQRIWKHSHUPDQHQWKXPDQFHOOOLQH&

GHULYHGIURPDVHFRQGDU\FKRQGURVDUFRPDLQ2OOLHU·VGLVHDVHVirchows Arch



 &OHWRQ-DQVHQ$0YDQ%HHUHQGRQN+0%DHOGH+-%RYpH-90*.DUSHULHQ

0+RJHQGRRUQ3&:(VWURJHQVLJQDOOLQJLVDFWLYHLQFDUWLODJLQRXVWXPRXUV

LPSOLFDWLRQVIRUDQWLHVWURJHQWKHUDS\DVWUHDWPHQWRSWLRQRIPHWDVWDVL]HGRU

LUUHVHFWDEOHFKRQGURVDUFRPDClin Cancer Res

 6FKUDJH <0 %ULDLUHGH %UXLMQ ,+ GH 0LUDQGD 1)&& YDQ 2RVWHUZLMN -

7DPLQLDX $+0 YDQ :H]HO 7 HW DO .LQRPH SURÀOLQJ RI FKRQGURVDUFRPD

UHYHDOV 6UFSDWKZD\ DFWLYLW\ DQG GDVDWLQLE DV RSWLRQ IRU WUHDWPHQW Cancer Res

 GH+HHU+36DQGHO0+*XHUWHQV*GH%*.RXGLMV001DJHONHUNH-)HWDO

&HOHFR[LELQKLELWVJURZWKRIWXPRXUVLQDV\QJHQHLFUDWOLYHUPHWDVWDVHVPRGHO

for colorectal cancer. Cancer Chemother Pharmacol

 *URVFK 6 0DLHU 7- 6FKLIIPDQQ 6 *HLVVOLQJHU * &\FORR[\JHQDVH &2;

LQGHSHQGHQWDQWLFDUFLQRJHQLFHIIHFWVRIVHOHFWLYH&2;LQKLELWRUVJ Natl



Cancer Inst

 6X%'LD]&UX](6/DQGLQL6%UXHJJHPHLHU5:6XSSUHVVLRQRIDURPDWDVH

LQKXPDQEUHDVWFHOOVE\DF\FORR[\JHQDVHLQKLELWRUDQGLWVDQDORJLQYROYHV

PXOWLSOH PHFKDQLVPV LQGHSHQGHQW RI F\FORR[\JHQDVH LQKLELWLRQ Steroids



 6RORPRQ 6' 0F0XUUD\ -- 3IHIIHU 0$ :LWWHV - )RZOHU 5 )LQQ 3 HW DO

&DUGLRYDVFXODUULVNDVVRFLDWHGZLWKFHOHFR[LELQDFOLQLFDOWULDOIRUFRORUHFWDO

adenoma prevention. N Engl J Med

 %UHVDOLHU566DQGOHU564XDQ+%RORJQHVH-$2[HQLXV%+RUJDQ.HW

DO&DUGLRYDVFXODUHYHQWVDVVRFLDWHGZLWKURIHFR[LELQDFRORUHFWDODGHQRPD

chemoprevention trial. N Engl J Med

 )UDPSWRQ-(.HDWLQJ*0&HOHFR[LEDUHYLHZRILWVXVHLQWKHPDQDJHPHQW

of arthritis and acute pain. Drugs